CTMX - CIK 0001501989
The table below shows CytomX Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.83M | $34.19M | $49.04M | $47.60M | $40.58M | $43.25M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $646.00K | $1.63M | $1.87M | $1.96M | $3.35M | $2.77M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $353.10M |
| $149.22M |
| $164.62M |
| $86.63M |
| $124.18M |
| $143.08M |
| Property, plant & equipment | $1.09M | $1.72M | $1.95M | $2.23M | $2.94M | $3.32M |
| Goodwill | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K |
| Total assets | $359.36M | $158.25M | $175.06M | $98.50M | $138.98M | $159.22M |
| Accounts payable | $1.37M | $646.00K | $227.00K | $276.00K | $1.42M | $611.00K |
| Total current liabilities | $34.02M | $41.03M | $39.22M | $50.20M | $119.23M | $142.86M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $39.41M | $50.87M | $55.15M | $73.45M | $162.43M | $190.45M |
| Retained earnings | -$730.20M | -$682.44M | -$668.21M | -$668.05M | -$710.46M | -$716.19M |
| Total equity | $319.94M | $107.39M | $119.91M | $25.05M | -$23.45M | -$31.23M |